PRESS RELEASE – FOR IMMEDIATE RELEASE

Gustave Roussy and IntegraGen announce the completion of one thousand analyses over an initial 18 month time period with a clinical research sequencing platform

The sequencing platform, which is operated by IntegraGen at Gustave Roussy and was launched in May 2014, was utilized to identify genetic mutations from DNA and RNA extracted from the tumors of over 400 cancer patients. The results obtained were utilized to assist in the identification of the most appropriate therapies for these patients. Initial results from this platform were recently presented at the 1st Molecular Analysis for Personalized Therapy (MAP) Conference held on October 23rd and 24th in Paris, France.

VILLEJUIF, EVRY France, November 11th, 2015 - Gustave Roussy, Europe’s leading center in the fight against cancer, and IntegraGen, the French leader in genomics services, today announced the achievement of one thousand genomic analyses utilizing their combined sequencing platform. The molecular profiles of cancer patients were analyzed as part of the MOSCATO (Molecular Screening for Cancer Treatment Optimization) and MAPPYACTS (Molecular Profiling for Pediatric and Young Adult Cancer Treatment Stratification) personalized medicine clinical trials being conducted at Gustave Roussy. The ability to deliver these results in less than three weeks demonstrates the capability of these teams to routinely sequence DNA (exome) and RNA (transcriptome) from tumors for clinical research purposes.

Results availability consistent with timelines needed for therapeutic decision making

With results of analyses available in less than three weeks, clinicians were able to enroll patients an appropriate personalized medicine clinical trial enabling the patient to receive the most suitable treatment for the genomic profile associated with their tumor within a timeframe compatible with therapeutic decision making. This included many patients benefiting from the ability to enter Phase 1 clinical trials being conducted at Gustave Roussy.

Results from clinical research data demonstrated greater data availability

Data from the first 300 analyses performed were presented at the MAP conference recently held in Paris. Results obtained from the sequencing platform were as sensitive (94%) as those typically obtained from conventional methodologies utilized for the analysis of a targeted panel of 75 genes. Additionally, an analysis of the full exome sequencing data from these first cases demonstrated that 38% of the results provided contained clinically relevant information. In addition to the information provided by the targeted analysis, a variety of additional genetic anomalies which were not previously available were identified based on the analysis of the RNA from the patient’s tumors.

Utilizing this platform provided information on both markers that reflect the biological activation of the tumor and the mutational load indicating the presence of neoantigens in tumors. A large mutational load is typically associated with a larger, more difficult to treat tumor. The use of the present approach to analyze oncology markers can assist with the selection of a therapeutic strategy and help guide the patient to the best strategy from personalized medicine perspective. The objective of this approach is to optimize the treatment of patients with advanced disease in order to define more targeted and better adapted treatments.
Capture of data which supports future research initiatives

The sequencing data obtained from the current and future analyses of patient’s tumors will also generate a significant amount of information that can be processed and subsequently added to a database which catalogues the description of each tumor and provide insight on proliferation mechanisms, dissemination and resistance of each cancer in association with the molecular findings. This information will ultimately assist in predicting the response to treatments, help patients avoid unnecessary therapies, and identify therapy approaches which are contraindicated based on the patient’s mutational status.

Based on the results obtained to date, Gustave Roussy and IntegraGen have agreed to move to a second stage of their partnership and plan to develop and expanded use of the platform by increasing access of this unit to new types of tests, including projects in the field of immune-oncology and the study of neoantigens.

Gustave Roussy and IntegraGen are also engaged in a separate partnership with INSERM and Sogeti High Tech which is aimed towards improving the availability of bioinformatic information to biologists and oncologists. This initiative, called the ICE (Interpretation of Clinical Exome) project, is focused on developing a scientific software solution that assists with the interpretation of data from the genome sequencing providing a decision-making tool for laboratories which analyze sequencing data from cancer patients.

"With the IntegraGen team we have demonstrated the feasibility of achieving these analyzes utilizing an integrated process management as part of our personalized medicine clinical trials. This helps us to actively participate in the implementation of the Cancer Plan 3 of which one of its objectives is to develop the ability to explore the tumor exome," commented Professor Eric Solary, Director of Research at Gustave Roussy.

"Gustave Roussy’s expertise in oncology and experience with conducting clinical trials combined with IntegraGen’s mastery of genomics has enabled us to develop together a complete sequencing and bioinformatics solution," stated Bernard Courtieu, Chairman and CEO of IntegraGen. "From obtaining a biological sample to delivering sequencing results via a computer interface that enables the clinician to easily interpret a patient’s genomic data, we are providing a solution that is the first of its kind in Europe which also benefits patients who agree to participate in clinical research programs focusing on personalized medicine.”

About the MAP Conference

The 1st MAP Conference (Molecular Analysis for Personalized therapy) was held on October 23-24, 2015 and was a joint initiative of UNICANCER, the European Society for Medical Oncology (ESMO) and Cancer Research UK (CRUK). The meeting, co-founded by Prof. Fabrice André and Prof. Jean-Charles Soria from Gustave Roussy, and Prof. Charles Swanton of the London Research Institute, explored the clinical interpretation of molecular tests for metastatic cancers and the development of new biotechnologies which have revolutionized the applications of personalized therapy. This two day meeting was had over 400 attendees from Europe, North America and Asia and featured the latest clinical developments in personalized medicine and results from studies in this field.

About Gustave Roussy

Gustave Roussy is the leading Cancer Centre in Europe. It is a center where all the skills in cancer care are focused on the patient. It comprises 3,000 professional staff who are engaged in care, research and teaching.

ABOUT INTEGRAGEN

IntegraGen is a company that specializes in deciphering the human genome and produces relevant and easily interpretable data for academic and private laboratories. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients.

As of December 31, 2014, IntegraGen had 34 employees and had generated revenue of €6 million in 2014. Based in the Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts.


For more information on IntegraGen visit www.integragen.com.

CONTACTS

INTEGRAGEN
Bernard COURTIEU
President, Managing Director
Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

GUSTAVE ROUSSEY
Christine Lascombe
Head of Communication
christine.lascombe@gustaveroussy.fr
Tel.: +33 (0)1 42 11 41 75

NEWCAP.
Investor and Media relations
Emmanuel HUYNH
Louis-Victor DELOUVRIER
integragen@newcap.fr
Tel.: +33 (0)1 44 71 94 94